Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia

作者：Ballen Karen K^*; Woolfrey Ann E; Zhu Xiaochun; Ahn Kwang Woo; Wirk Baldeep; Arora Mukta; George Biju; Savani Bipin N; Bolwell Brian; Porter David L; Copelan Ed; Hale Gregory; Schouten Harry C; Lewis Ian; Cahn Jean Yves; Halter Joerg; Cortes Jorge; Kalaycio Matt E; Antin Joseph; Aljurf Mahmoud D; Carabasi Matthew H; Hamadani Mehdi; McCarthy Philip; Pavletic Steven; Gupta Vikas; Deeg H Joachim; Maziarz Richard T; Horowitz Mary M; Saber Wael

来源：Biology of Blood and Marrow Transplantation, 2012, 18(9): 1446-1454.

DOI：10.1016/j.bbmt.2012.03.009

• Transplantation
• PV
• ET

Allogeneic hematopoietic cell transplantation (HCT) is curative for selected patients with advanced essential thrombocythemia (ET) or polycythemia vera (PV). From 1990 to 2007, 75 patients with ET (median age 49 years) and 42 patients with PV (median age 53 years) underwent transplantations at the Fred Hutchinson Cancer Research Center (FHCRC; n = 43) or at other Center for International Blood and Marrow Transplant Research (CIBMTR) centers (n = 74). Thirty-eight percent of the patients had splenomegaly and 28% had a prior splen ectomy. Most patients (69% for ET and 67% for PV) received a myeloablative (MA) conditioning regimen. Cumulative incidence of neutrophil engraftment at 28 days was 88% for ET patients and 90% for PV patients. Acute graft-versus-host disease (aGVHD) grades II to IV occurred in 57% and 50% of ET and PV patients, respectively. The 1-year treatment-related mortality (TRM) was 27% for ET and 22% for PV. The 5-year cumulative incidence of relapse was 13% for ET and 30% for PV. Five-year survival/progression-free survival (PFS) was 55%/47% and 71%/48% for ETand PV, respectively. Patients without splenomegaly had faster neutrophil and platelet engraftment, but there were no differences in TRM, survival, or PFS. Presence of myelofibrosis (MF) did not affect engraftment or TRM. Over 45% of the patients who undergo transplantations for ET and PV experience long-term PFS.

• 出版日期2012-9